Skip to main
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus is focused on developing and commercializing innovative medical devices, and its strategic investments in PNS, PRP, ultrasonics, and international markets suggest strong potential for long-term growth. The company also has a solid core business, with sustainable competitive advantages in its pain injection franchise, bone graft substitutes, and fracture care products. Furthermore, the company's debt paydown has opened up further capital allocation options, including potential stock buybacks and M&A opportunities, enhancing its potential for steady expansion and margin improvement.

Bears say

Bioventus is facing potential challenges in their PNS business due to the need to invest in infrastructure and build a commercial team following the launch of new products. This investment may not yield immediate returns and could be a strain on financial performance in the short term. Additionally, the company is subject to regulatory approval processes which can be costly and time-consuming, potentially leading to delays in product launch and revenue generation. This, combined with potential impacts of changes in reimbursement rates, could negatively impact the company's financial condition and performance.

Bioventus (BVS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Bioventus (BVS) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.